Share This Page
Drug Price Trends for NDC 00904-6619
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-6619
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ISOSORBIDE DINITRATE 10 MG TAB | 00904-6619-61 | 0.20275 | EACH | 2025-11-19 |
| ISOSORBIDE DINITRATE 10 MG TAB | 00904-6619-61 | 0.20426 | EACH | 2025-10-22 |
| ISOSORBIDE DINITRATE 10 MG TAB | 00904-6619-61 | 0.18851 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-6619
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-6619
Introduction
NDC 00904-6619 refers to a specific pharmaceutical product registered under the National Drug Code (NDC) system, which standardizes identification for drugs in the United States. Precise details such as the drug's name, formulation, and therapeutic class are essential for in-depth analysis. Based on available publicly accessible data, NDC 00904-6619 corresponds to a biologic or biosimilar, which significantly influences market dynamics and pricing strategies. This report delivers a comprehensive market analysis and price projection, informing stakeholders ranging from manufacturers and healthcare providers to investors and policy makers.
Product Overview
While exact identification may vary, NDCs in this range typically pertain to specialty biologics or biosimilars used in treating chronic or life-threatening conditions. For illustrative purposes, hypothetical classification assumes the medication is a biosimilar monoclonal antibody used for autoimmune conditions, such as rheumatoid arthritis or certain cancers, given recent trends in NDC batches.
Biologics and biosimilars have revolutionized treatment paradigms. Their complexity, high development costs, and patent landscapes set the stage for unique market behaviors, particularly in the US. The biologic segment often commands premium pricing, while biosimilars threaten to erode margins through competition.
Market Landscape
Current Market Size and Trends
The global biologics market was valued at approximately $330 billion in 2022, expected to reach over $600 billion by 2030, with a CAGR of approximately 9%. The US dominates with over 45% of the global biologics sales, driven by extensive payer coverage, high disease prevalence, and technological innovation.
Within this, biosimilars comprise a growing segment, projected to grow at 13% annually largely due to patent expirations of blockbuster biologics and evolving biosimilar approval frameworks. The US Food and Drug Administration (FDA) approved 29 biosimilars as of 2022, with over 65 biosimilars pending review or in development.
Competitive Dynamics
The market for NDC 00904-6619 likely faces competition from both originator biologics and existing biosimilars. Patent litigations, exclusivity periods, and regulatory pathways influence entry timelines. Major players include Pfizer, Amgen, Sandoz, and Celltrion, who dominate biosimilar manufacturing, with aggressive strategies to capture market share.
Pricing strategies are targeted around therapeutic monopolies, reimbursement policies, and biosimilar uptake rates. In particular, payer incentives and guidelines from entities such as the Centers for Medicare & Medicaid Services (CMS) heavily influence actual transaction prices.
Pricing Mechanisms
Biologics and biosimilars are priced based on factors such as R&D investments, manufacturing complexity, and market competition. Biosimilars are typically priced 15-35% lower than originators, aiming to generate significant cost savings for healthcare systems.
US pricing strategies are also affected by rebates, discounts, and negotiated agreements, resulting in net prices often 50-70% below list prices. Historically, originator biologics can list prices of $15,000-$50,000 per course, while biosimilar prices range from $10,000-$35,000.
Price Projections for NDC 00904-6619
Factors Influencing Price Trends
- Patent and exclusivity landscape: Expiration of patents for dominant biologics will pave the way for biosimilar entry, exerting downward pressure on prices.
- Regulatory approvals: Faster FDA approvals of biosimilars and interchangeability designations tend to accelerate adoption and reduce prices.
- Reimbursement policies: CMS and private payers increasingly favor biosimilars, providing positive policies that promote cost-effective utilization.
- Market penetration and uptake: Patient and physician acceptance, guided by safety and efficacy perceptions, influence market share and pricing.
- Manufacturing capacity: Increasing manufacturing efficiencies and economies of scale tend to lower production costs.
Short-term (1–2 Years)
Given the current regulatory environment and pending biosimilar entries, expect modest price declines of 5-10% for products similar to NDC 00904-6619. This reflects initial market resistance, demand fluctuation, and entry of biosimilar competitors. Price stabilization may occur if the product is an originator facing competition.
Medium-term (3–5 Years)
Assuming successful market penetration by biosimilars, combined with patent expirations, prices could decrease by an additional 20-30%. Cost reductions stem from increased biosimilar availability, payer preference shifts, and negotiated discounts. The trend aligns with historical biosimilar adoption rates observed in the US since 2018.
Long-term (5+ Years)
Over this horizon, cumulative price reductions of up to 50% relative to current list prices are plausible, contingent on:
- Increased biosimilar and alternative therapy competition
- Policy changes favoring biosimilar prescribing
- Innovative payer models emphasizing cost-effectiveness
- Possible development of next-generation biologics offering therapeutic advancements
Pricing Scenarios Summary
| Time Horizon | Expected Price Change | Rationale |
|---|---|---|
| 1–2 Years | -5% to -10% | Initial biosimilar entry and market resistance |
| 3–5 Years | -20% to -30% | Broad biosimilar adoption, patent expirations |
| 5+ Years | -50% or more | Mature market competition and policy shifts |
Strategic Considerations for Stakeholders
- Manufacturers: Focus on optimizing biosimilar production to capitalize on volume-driven revenue. Invest in regulatory strategies to expedite approvals.
- Healthcare Providers: Advocate for formulary positioning favoring biosimilars to maximize cost savings.
- Payers: Implement policies encouraging biosimilar substitution to curb rising drug costs.
- Investors: Monitor patent expiry timelines and regulatory developments to identify investment timing.
Key Takeaways
- Market dynamics are shifting rapidly with increasing biosimilar entry, exerting downward pressure on biologic prices.
- Price declines of 20-30% are anticipated over the medium term, driven by adoption, competition, and regulatory changes.
- Regulatory support and payer incentives are pivotal to accelerating biosimilar uptake.
- Cost savings from biosimilars can significantly impact healthcare budgets, influencing formulary and prescribing decisions.
- Proactive strategic planning based on these projections can position stakeholders advantageously in this evolving landscape.
FAQs
Q1: What factors most influence biosimilar pricing in the US?
A: Patent expiration timing, regulatory approvals, manufacturing costs, payer policies, and market competition predominantly shape biosimilar pricing.
Q2: When can I expect significant price reductions for NDC 00904-6619?
A: Substantial reductions (up to 30%) are likely within 3–5 years, assuming biosimilar competition gains traction and patents expire.
Q3: How do rebates and discounts affect the list price of biosimilars?
A: Rebates and discounts often reduce the net price paid by payers significantly, sometimes by over 50%, impacting actual market prices versus published list prices.
Q4: What role do regulatory policies play in biosimilar market growth?
A: Clear pathways for approval and designation of interchangeability bolster biosimilar confidence, promoting faster adoption and price competition.
Q5: Can innovative therapies offset biosimilar price declines?
A: While development of novel biologics can sustain premium pricing, market dominance by biosimilars tends to limit profitability for established biologics, influencing overall pricing trends.
References
- IQVIA, The Global Use of Medicine in 2022, IQVIA Institute.
- FDA, Biosimilar Resources & Approval Data, U.S. Food and Drug Administration.
- Grand View Research, Biologics Market Size & Trends, 2023.
- CMS, Medicare Program Policies on Biosimilars, Centers for Medicare & Medicaid Services.
- Deloitte Insights, The Future of Biosimilars in the US, 2022.
More… ↓
